Anti-Parkinson Drugs Market Growth Analysis With Investment Opportunities For 2024 – 2033

The Business Research Company's Anti-Parkinson Drugs Market Growth Analysis With Investment Opportunities For 2024 – 2033

LONDON, GREATER LONDON, UK, August 22, 2024 /EINPresswire.com/ -- The global anti-parkinson drugs market has experienced significant growth in recent years, increasing from $9.73 billion in 2023 to an anticipated $10.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. This growth has been driven by factors such as an aging population, increasing disease prevalence, advancements in healthcare infrastructure, and research. The market is projected to reach $13.36 billion by 2028, growing at a CAGR of 6.4% during the forecast period. Key drivers include growing awareness, biotechnological advancements, and emerging markets.

Increasing Geriatric Population Drives Market Growth
The growing geriatric population, coupled with the rising incidence of Parkinson's disease (PD), is a major factor driving the demand for anti-Parkinson drugs. Parkinson's disease primarily affects individuals over the age of 60, and with the global population aging rapidly, the demand for effective treatments is increasing. For instance, according to the World Health Organization, by 2030, one in six individuals globally will be 60 or older, with the number expected to double by 2050 to 2.1 billion. Similarly, in the UK, the elderly population is projected to account for 24% of the total population by 2043. The increasing geriatric population is, therefore, a key driver for the growth of the anti-Parkinson drugs market.

Explore comprehensive insights into the global anti-Parkinson drugs market with a detailed sample report:
https://www.thebusinessresearchcompany.com/sample_request?id=3462&type=smp

Key Players and Market Trends
Major companies in the anti-Parkinson drugs market include GlaxoSmithKline PLC, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, and UCB S.A. These companies are focusing on innovative product development and strategic acquisitions to strengthen their market positions.
For instance, in October 2023, AbbVie Inc., a leading pharmaceutical company, acquired Mitokinin, a biotechnology firm specializing in treatments for Parkinson's disease, for $110 million. This acquisition is expected to bolster AbbVie's neuroscience pipeline and provide new treatment options for Parkinson's patients.

Segments
• Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-Inhibitors, Anticholinergics, Other Drugs
• Route of Administration: Oral, Injection, Transdermal
• Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Geographical Insights: North America Leads, Middle East Poised for Fastest Growth
North America was the largest region in the anti-Parkinson drugs market in 2023, driven by advanced healthcare infrastructure and a high prevalence of Parkinson's disease. The Middle East, however, is expected to be the fastest-growing region during the forecast period, owing to increasing investments in healthcare and rising awareness about Parkinson's disease.

Access the complete report for an in-depth analysis of the global anti-Parkinson drugs market:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Anti-Parkinson Drugs Global Market Report 2024 from The Business Research Company covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Anti-Parkinson Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on anti-parkinson drugs market size, anti-parkinson drugs market drivers and trends, anti-parkinson drugs market major players, anti-parkinson drugs competitors' revenues, anti-parkinson drugs market positioning, and anti-parkinson drugs market growth across geographies. The anti-parkinson drugs market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Dermatology Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Cardiovascular Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Central Nervous System Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn